Research
Hormonal
Androstenedione supplements do not produce anabolic effects or strength improvements in eugonadal men, regardless of age or training status.
Do not rely on androstenedione supplements to build muscle. Studies show that even at 300mg daily combined with training, it does not increase strength more than placebo in either young or older men. The conversion to testosterone is too low to be effective.
GoodRefutesHIGH confidence
This study has been replicated in older men using a similar design... The results of both studies were similar: neither younger nor older subjects who received androstenedione showed greater increases in strength than those who received placebo... No published studies report effective anabolic activity of suprapharmacologic doses of androstenedione.
Why this rating
Based on multiple controlled studies (King et al., Leder et al., Broeder et al.) showing no strength benefit.
Source
Anabolic Steroids
Cynthia M. Kuhn · Recent Progress in Hormone Research · 2002
DOI 10.1210/rp.57.1.411
narrative_reviewCited 166×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Suprapharmacologic doses of anabolic-androgenic steroids (AAS) increase muscle mass and strength in eugonadal men, whereas physiologic doses do not.Good
- Suprapharmacologic doses of AAS increase muscle mass and strength in eugonadal men through mechanisms involving androgen receptor upregulation, satellite cell activation, and potentially anticatabolic effects, rather than just increased protein synthesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →